The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 ...

Some five years into a pneumococcal vaccine patent dispute in South Korea, SK Bioscience has emerged victorious over Pfizer ... contribute to a stable global vaccine supply, and achieve ...

In 2020, Pfizer claimed ... transfers through local partnerships are also being pursued in parallel. Looking ahead, SK bioscience aims to expand its presence in the global pneumococcal vaccine ...

While gaps persist in workforce retention, infrastructure, and equitable access, the transformation of Nigeria’s health ...

3SBio will grant Pfizer exclusive global rights, not including China, to develop, manufacture and commercialize SSGJ-707, a ...

Pfizer just penned a $6 billion licensing deal with China's 3SBio to develop and commercialize a cancer drug, SSGJ-707. The ...

The Dementia Discovery Fund ("DDF"), managed by SV Health Investors, today announced the final closing of its second fund, DDF-2, with $269m in commitments. DDF is the world's largest family of ...